试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-23
A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
编号:NCT02864290登记状态:提前终止企业 / 申办者:Astellas Pharma Global Development, Inc.
药物 / 成分:ASP1235
登记的停止原因(原文):Study was terminated due to lack of efficacy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-23
Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
编号:NCT03809624登记状态:提前终止企业 / 申办者:Inhibrx Biosciences, Inc
药物 / 成分:INBRX-105 - PDL1x41BB antibody、Pembrolizumab
登记的停止原因(原文):Program terminated due to lack of meaningful efficacy signal.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-23
A Study to Learn About the Effects of Sisunatovir in Infants With Respiratory Syncytial Virus Lower Respiratory Tract Infection.
编号:NCT04225897登记状态:提前终止企业 / 申办者:Pfizer
药物 / 成分:RV521、Placebo
登记的停止原因(原文):Part A and Part B were completed but Pfizer terminated Part C due to strategic consideration. There were no safety concerns in the decision to stop Part C and no changes to the risk-benefit for participants who received RV521 in the study.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-23
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
编号:NCT05047523登记状态:提前终止企业 / 申办者:Alexion Pharmaceuticals, Inc.
药物 / 成分:ALXN1840、Standard of Care
登记的停止原因(原文):Sponsor decision to terminate the program
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-23
A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19
编号:NCT05375760登记状态:提前终止企业 / 申办者:AstraZeneca
药物 / 成分:AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])、AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
登记的停止原因(原文):Sponsor terminated after review of FDA's request to halt further dosing (30Mar2023) given that AZD7442 is not active against \>99% of the currently circulating SARS-CoV-2 variants in the USA, the benefit risk assessment may not be favorable
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-22
Optimum Immunosuppression in Renal Transplant Recipients.New Onset Diabetes After Transplantation
编号:NCT01002339登记状态:提前终止企业 / 申办者:Armando Torres Ramírez
药物 / 成分:Tacrolimus with rapid steroid withdrawal、Tacrolimus with steroids minimization、CsA with steroid minimization
登记的停止原因(原文):Terminated: higher rate of acute rejection in the Cyclosporin A group
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-22
TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.
编号:NCT02980029登记状态:提前终止企业 / 申办者:Mark Evers
药物 / 成分:TVB-2640、Placebo
登记的停止原因(原文):Study was terminated by the PRMC for low accrual
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-22
A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD)
编号:NCT04184882登记状态:提前终止企业 / 申办者:Astellas Pharma Inc
药物 / 成分:Bocidelpar、Placebo
登记的停止原因(原文):Operational Reasons
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-21
Randomized, Double-Blind, Placebo-Controlled Pilot Study on the Safety and Effectiveness of LUCEMYRA During an Opioid Taper in Treatment of Withdrawal
编号:NCT04070157登记状态:提前终止企业 / 申办者:USWM, LLC (dba US WorldMeds)
药物 / 成分:Lofexidine、Placebo
登记的停止原因(原文):COVID pandemic and enrollment issues necessitating an adjustment to the study design.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-10-21
A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101
编号:NCT05629741登记状态:提前终止企业 / 申办者:Clarametyx Biosciences, Inc.
药物 / 成分:CMTX-101、Placebo
登记的停止原因(原文):Study was stopped due to slow enrollment. No safety issues were identified. Part 1 (healthy volunteers) fully enrolled; Part 2 (CABP patients) enrolled the first 2 cohorts. Data currently under review. Results will be posted when final.
查看官方原始记录 ↗